Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer
Launched by WROCLAW MEDICAL UNIVERSITY · Jan 29, 2024
Trial Information
Current as of July 06, 2025
Completed
Keywords
ClinConnect Summary
The aim of our prospective study was to determine the prognostic impact of the inflammatory response and indicators of nutritional status on recurrence and progression of non-muscle invasive bladder cancer (NMIBC) in patients undergoing transurethral resection of bladder tumour (TURBT). We evaluated six biomarkers, 3 in blood serum: soluble urokinase plasminogen activator receptor (sUPAR), plasminogen activator inhibitor-1 (PAI-1), interleukin 8 (IL-8) and 3 in urine: apolipoprotein E (APOE), vascular endothelial growth factor (VEGF), interleukin 8 (IL-8). Furthermore, following indicators ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed informed consent form
- • Presence or suspicion of tumour in urinary bladder
- • Qualification for the first transurethral resection of bladder tumour
- Exclusion Criteria:
- • 1. age \< 18 years
- • 2. active urinary tract infection
- • 3. active autoimmune disease
- • 4. end-stage renal failure and renal replacement therapy
- • 5. active hepatitis A, B or C
- • 6. active HIV infection
- • 7. pregnancy
- • 8. factors disqualifying the patient from adjuvant treatment (intravesical immunotherapy or intravesical chemotherapy)
- • 9. bladder tumour stage T2 or more, or urothelial tumour in a location other than the urinary bladder
- • 10. other cancer or systemic anticancer treatment carried out up to 5 years ago
- • 11. factors disqualifying the patient from surgical treatment, e.g. coagulopathies
- • 12. lack of patient consent to collection of blood and urine samples and to follow-up visits
About Wroclaw Medical University
Wrocław Medical University is a prestigious academic institution located in Wrocław, Poland, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive expertise in healthcare and biomedical sciences to facilitate innovative research initiatives aimed at improving patient outcomes. With a strong emphasis on ethical practices and regulatory compliance, Wrocław Medical University collaborates with a diverse network of healthcare professionals and researchers to conduct rigorous clinical trials that contribute to the development of new therapies and enhance the understanding of various medical conditions. Its dedication to scientific excellence and patient safety positions the university as a key player in the global clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wrocław, , Poland
Patients applied
Trial Officials
Klaudia Bardowska, MD
Principal Investigator
Wroclaw Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported